Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

Benzinga Newsdesk www.benzinga.com Positive 89.1%

Neg 0% Neu 0% Pos 89.1%

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.